Germany · Delayed Price · Currency is EUR bioXXmed AG Statistics
Total Valuation
bioXXmed AG has a market cap or net worth of EUR 209,336. The enterprise value is 390,666.
| Market Cap | 209,336 |
| Enterprise Value | 390,666 |
Important Dates
The last earnings date was Friday, July 3, 2026.
| Earnings Date | Jul 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
bioXXmed AG has 271,865 shares outstanding.
| Current Share Class | 271,865 |
| Shares Outstanding | 271,865 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.51 |
| PB Ratio | -209,336.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 356.12
| Current Ratio | 356.12 |
| Quick Ratio | 234.64 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.94 |
Financial Efficiency
Return on equity (ROE) is -229.36% and return on invested capital (ROIC) is -48.18%.
| Return on Equity (ROE) | -229.36% |
| Return on Assets (ROA) | -35.44% |
| Return on Invested Capital (ROIC) | -48.18% |
| Return on Capital Employed (ROCE) | -57.92% |
| Weighted Average Cost of Capital (WACC) | 12.20% |
| Revenue Per Employee | 8,366 |
| Profits Per Employee | -182,695 |
| Employee Count | 2 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -92 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.44% in the last 52 weeks. The beta is 4.99, so bioXXmed AG's price volatility has been higher than the market average.
| Beta (5Y) | 4.99 |
| 52-Week Price Change | -62.44% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.20 |
| Relative Strength Index (RSI) | 37.99 |
| Average Volume (20 Days) | 53 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioXXmed AG had revenue of EUR 16,731 and -365,390 in losses. Loss per share was -1.34.
| Revenue | 16,731 |
| Gross Profit | 16,731 |
| Operating Income | -271,228 |
| Pretax Income | -365,482 |
| Net Income | -365,390 |
| EBITDA | -271,193 |
| EBIT | -271,228 |
| Loss Per Share | -1.34 |
Balance Sheet
The company has 203,668 in cash and 385,000 in debt, with a net cash position of -181,332 or -0.67 per share.
| Cash & Cash Equivalents | 203,668 |
| Total Debt | 385,000 |
| Net Cash | -181,332 |
| Net Cash Per Share | -0.67 |
| Equity (Book Value) | -1 |
| Book Value Per Share | -0.00 |
| Working Capital | 308,241 |
Cash Flow
| Operating Cash Flow | -335,000 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 35 |
| Net Borrowing | 385,000 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,621.11% |
| Pretax Margin | -2,184.46% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
bioXXmed AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -174.55% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jan 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
bioXXmed AG has an Altman Z-Score of -131.21 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -131.21 |
| Piotroski F-Score | 3 |